Saito et al. adopted a combination of FLT3 TKI and B-cell lymphoma 2 (Bcl-2) inhibitor in AML PDXs and identified prominently higher sensitivity to apoptosis induction compared to monotherapy[18]. The gene discussed is FLT3; the disease is acute myeloid leukemia.